论文部分内容阅读
本研究探讨符合线路SPECT18F-FDG显像检查对淋巴瘤患者诊断及治疗后监测复发的应用价值。回顾性分析我院1998-2008年病理活检和免疫组织化学确诊的淋巴瘤患者71例次的SPECT/PET检查结果。结果表明:28例患者初次治疗前行SPECT/PET检查的准确率100%,而CT准确率为81.7%。SPECT/PET和CT对病灶的检出灵敏度分别为85.7%和53.5%,两者有显著性差异(p=0.003)。SPECT/PET和CT对结外病灶的检出灵敏度分别为91.3%和56.5%,两者有显著性差异(p=0.007)。32例淋巴瘤患者在治疗结束后随访阶段共进行了43例次SPECT/PET检查。SPECT/PET对复发的阳性预测值为100%、阴性预测值为92.9%。6例患者为SPECT/PET先于临床症状、体征及其他实验室、影像学检查发现疾病复发。结论:SPECT/PET检查结果对淋巴瘤患者诊断和监测复发有重要意义。
This study was to evaluate the value of line SPECT18F-FDG imaging in the diagnosis and treatment of lymphoma recurrence after treatment. Retrospective analysis of our hospital 1998-2008 pathological biopsy and immunohistochemical diagnosis of lymphoma patients with 71 cases of SPECT / PET test results. The results showed that the accuracy of SPECT / PET examination before the first treatment in 28 patients was 100%, while the accuracy of CT was 81.7%. Sensitivity of SPECT / PET and CT to lesions was 85.7% and 53.5%, respectively, with significant difference (p = 0.003). The detection sensitivities of SPECT / PET and CT to extranodal lesions were 91.3% and 56.5%, respectively, with significant difference (p = 0.007). Thirty-two patients with lymphoma underwent 43 SPECT / PET examinations at the end of follow-up. The positive predictive value of SPECT / PET for recurrence was 100%, and the negative predictive value was 92.9%. Six patients were diagnosed with SPECT / PET prior to clinical symptoms, signs and other laboratory imaging findings. Conclusion: The results of SPECT / PET examination are of great importance for the diagnosis and monitoring of recurrence in patients with lymphoma.